Federal Circuit denies rehearing in ‘patent dance’ case
19-10-2015
Dima Sobko / Shutterstock.com
Drug maker Sandoz has officially launched its Zarxio (filgrastim-sndz) biosimilar after a US appeals court declined to issue an injunction that would have prevented it from being sold.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Amgen; Sandoz; Novartis; biosimilar; Zarxio; FDA; Food and Drug Administration; generics
